|

IMproving PAtient UndeRstanding of GEP TEst Results: Phase 4

RECRUITINGN/ASponsored by European Institute of Oncology
Actively Recruiting
PhaseN/A
SponsorEuropean Institute of Oncology
Started2024-09-06
Est. completion2025-12
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06703567

Summary

The primary aim of the study is to determine if provision of a patient information film about Oncotype DX improves patients' knowledge and understanding about Gene Expression Profiling (GEP) test and risk of recurrence results in early breast cancer (EBC) patients, identified by their clinical teams as potentially benefiting from having their tumor samples sent for GEP analysis.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* First presentation of early stage breast cancer with all known disease surgically removed
* Estrogen Receptor (ER) positive and Human Epidermal growth factor Receptor 2 (HER-2) negative
* No clear decision on whether chemotherapy should be given as adjunct based on current prognostic criteria
* Consented to GEP testing
* Able to give full informed consent to IMPARTER study
* Good comprehension of the Italian language
* Access to internet connection and devices (e.g. smart phone, tablet, laptop or desktop computer)

Exclusion Criteria:

* Other breast cancer diagnosis (e.g. Ductal carcinoma in situ, Metastatic)
* Unable to give fully informed consent
* Under 18 years of age
* Unable to understand and speak Italian
* No access to internet connection or devices

Conditions2

Breast CancerCancer

Browse More Trials

Cancer trialsBreast Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.